• 1
    El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-1127.
  • 2
    Lencioni RL, Llovet JM, Han G, Tak W-Y, Yang J, Leberre M-A, et al. Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): phase II, randomised, double-blind SPACE trial. J Clin Oncol 2012;30( suppl 4). Abstract LBA154.
  • 3
    Chao Y, Lee H-C, Lee T-Y; Yoon J, Han G, Yang J et al. START (study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma) trial. Presented at the Fifth Annual Conference of the International Liver Cancer Association; September 2–4,2011; Hong Kong, People's Republic of China. Abstract 0–026.
  • 4
    Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol 2011;29:3960-3967.
  • 5
    Schmitt CA. Immunotherapy: seek and destroy: oncolytic virus shows promise in phase I trial. Nat Rev Clin Oncol 2011;8:630.
  • 6
    Liu TC, Hwang T, Park BH, Bell J, Kirn DH. The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther 2008;16:1637-1642.
  • 7
    Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 2008;9:533-542.
  • 8
    Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011;477:99-102.
  • 9
    Heo J, Reid T, Ruo L, Bloomston M, Lim HY, Chung HC, et al. Randomized, controlled phase 2 clinical trial of JX594, a targeted multi-mechanistic oncolytic poxvirus, in patients with advanced hepatocellular carcinoma: final data [abstract LB-1]. Hepatology 2011;54:1426A.
  • 10
    Liapi E, Geschwind JF, Vali M, Khwaja AA, Prieto-Ventura V, Buijs M, et al. Assessment of tumoricidal efficacy and response to treatment with 18F-FDG PET/CT after intraarterial infusion with the antiglycolytic agent 3-bromopyruvate in the VX2 model of liver tumor. J Nucl Med 2011;52:225-230.
  • 11
    Ganapathy-Kanniappan S, Kunjithapatham R, Torbenson MS, Rao PP, Carson KA, Buijs M, et al. Human hepatocellular carcinoma in a mouse model: assessment of tumor response to percutaneous ablation by using glyceraldehyde-3-phosphate dehydrogenase antagonists. Radiology 2012;262:834-845.